Business1 outlet
A16z-Backed Biotech Braveheart Seeks $318.8 Million in US IPO
Braveheart Bio Inc., a clinical-stage biopharmaceutical company backed by venture capital firm Andreessen Horowitz (a16z), is pursuing an initial public offering (IPO) targeting up to $318.8 million in funding. The company's IPO filing reflects ongoing investor confidence in the biotech sector and adds to the current wave of biopharmaceutical companies going public.
Readers say
How does this story lean?
Outlet ratings above are Trace's curated source map. Vote here (same as on the home feed) — one vote per browser, changeable anytime. Rate individual outlets in the coverage list below.
How does this lean?
Comments
0No comments yet. Say what you noticed in the coverage.
Trending